Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province, China: An Open-labeled, Ambidirectional Cohort Study
Sponsor: Liaoning Chengda Biotechnology CO., LTD
A PHASE4 clinical study on Japanese Encephalitis and Vaccine Preventable Disease, this trial is ongoing. The trial is conducted by Liaoning Chengda Biotechnology CO., LTD and has accumulated 7 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Active Not Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Active Not Recruiting PHASE4
-
Dec 2022 — Jul 2024 [monthly]
Active Not Recruiting PHASE4
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE4
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 2 earlier versions
-
May 2021 — Sep 2022 [monthly]
Enrolling By Invitation PHASE4
-
Apr 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE4
First recorded
Mar 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Liaoning Chengda Biotechnology CO., LTD
- Zhejiang Provincial Center for Disease Control and Prevention
For direct contact, visit the study record on ClinicalTrials.gov .